Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia Clinical Trial

Official title:

Autologous Bone Marrow Transplant for Children With AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00667927
• Other study ID #: AMLREM
• Status: Completed
• Phase: Phase 1
• First received: April 24, 2008
• Last updated: April 25, 2008
• Start date: March 1991
• Est. completion date: January 2008

Study information

• Verified date: April 2008
• Source: St. Jude Children's Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).

Description:

The primary objective of this study was to estimate the continuous complete remission rate at 2 years post transplant for children with AML in first complete remission treated with autologous BMT.

Secondary objectives used transduction of marker genes into autologous marrow to determine the following:

1. whether the source of relapse after BMT for AML is residual malignant cells in the harvested marrow or in the patient, and whether marrow purging is therefore rational.

2. whether the majority of AML, which lack genetic markers, represent abnormalities in a multi-lineage progenitor cell, and whether therefore, auto grafting/intensified chemotherapy is ever likely to augment the cure rate.

3. the mechanisms of autologous reconstitution, and the effects of stimuli which modify the process.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: January 2008
• Est. primary completion date: January 1995
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

• Patients aged between 1 and 18 years at diagnosis with acute nonlymphocytic leukemia in first remission are eligible for this protocol.

• Patients enrolled on the AML-87 study in second or subsequent remission are eligible for this protocol.

Exclusion Criteria:

• Has an HLA-matched, MLC-compatible donor(unless parents and/or patient refuses transplant.

• Diagnosis of FAB M3 or FAB M3v (acute progranulocytic leukemia)

• Life expectancy limited by disease other than leukemia

• Significant cardiac disease (echo shortening fraction <25% or MUGA scan <50%)

• Severe renal dysfunction, i.e., creatinine clearance less than 60cc/1.73 m2/min

• Severe restrictive pulmonary disease (FCV less than 40% of predicted)

• Severe hepatic disease (bilirubin greater than 3 mg/dl or SGPT greater than 500IU)

• Severe personality disorder or mental illness

• Previous severe cystitis from cyclophosphamide

• Previous total dose of anthracyclines of >450 mg/m2

• Sever infection that on evaluation by the PI precludes ablative chemotherapy or successful transplantation

• Previous autologous transplant

• HIV reactivity

• Karnofsky score <70%

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Busulfan
See Detailed Description section for description of treatment plan.
• Cyclophosphamide
See Detailed Description section for description of treatment plan.
• Mesna
See Detailed Description section for description of treatment plan.

Locations

Country	Name	City	State
United States	St. Jude Children's Research Hospital	Memphis	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
St. Jude Children's Research Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To estimate the continuous complete remission rate at 2 years for children with AML in first complete remission treated with Autologous Bone Marrow Transplant (ABMT).		2 years post transplant	Yes

External Links

•   Link